The Effect of Recombinant Baculovirus (BacG-CMV-P53) Mediated Gene Therapy in the HT-1376 Bladder Cancer Cell Line.
- Author:
Hong Jin SUH
1
;
Dong Hwan LEE
;
Ji Youl LEE
;
Soon Young PAIK
Author Information
1. Departments of Urology, The Catholic University of Korea. uroljy@catholic.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Baculovirus;
Bladder cancer;
Gene therapy
- MeSH:
Baculoviridae*;
Blotting, Western;
Cell Line*;
Cell Survival;
Genetic Therapy*;
GTP-Binding Proteins;
Humans;
Recurrence;
Urinary Bladder Neoplasms*;
Urinary Bladder*;
Vesicular Stomatitis
- From:Korean Journal of Urology
2004;45(11):1156-1161
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: In preliminary studies, it was found that mammalian cells can be infected by recombinant baculovirus in vitro. Therefore, the potential use of recombinant baculovirus(BacG-cytonegalovirus(CMV)-P53) for the bladder gene therapy was investigated. MATERIALS AND METHODS: The recombinant Baculovirus(BV) pseudotyped was developed with the vesicular stomatitis virus(VSV) G protein. The presence of the VSV-G protein in purified BV preparations was confirmed by Western blotting analysis. The bladder cancer cells of human(HT-1376) were infected with various multiplicity of infection(MOI) of the BV, and the percentage of apoptotic cells determined by methyl thiazolyl tetrazolium(MTT) assay. RESULTS: The suppression effect of the recombinant BV with a P53 insertion in human bladder cancer cells(HT-1376) increased as the MOI of the recombinant BV increased; 100% cell survival in the group with PBS, and 81.6+/-4.3, 52.0+/-5.6 and 39.8+/-3.7% at 1, 10 and 100 MOI, respectively (p<0.05). CONCLUSIONS: Significant growth suppression was observed following infection with BacG-CMV-P53 in a human bladder cancer cell line. This observation suggests that BacG-CMV-P53 may be a potentially effective agent to prevent recurrence for P53 mutated bladder cancer. Bladder gene therapy using recombinant baculovirus could be a safe and effective treatment of bladder cancer.
